Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases
| Autor: | Nobuyuki Mizunuma, Junji Yamamoto, Shinichi Miyagawa, Masanori Teruya, Tadatoshi Takayama, Michiro Takahashi, Masayoshi Ijichi, Kiyoshi Hasegawa, Masatoshi Makuuchi, Fuyo Yoshimi, Masaru Oba, Seiji Kawasaki, Yutaka Matsuyama, Akio Saiura, Hiroto Koyama, Takashi Kokudo, Norihiro Kokudo, Soichiro Ishihara |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Adjuvant chemotherapy medicine.medical_treatment Antineoplastic Agents 030230 surgery Gastroenterology Disease-Free Survival 03 medical and health sciences Young Adult 0302 clinical medicine Japan Internal medicine Recurrence free survival medicine Adjuvant therapy Hepatectomy Humans In patient Aged Aged 80 and over business.industry Incidence Hazard ratio Liver Neoplasms Patient survival Middle Aged Prognosis Confidence interval Chemotherapy Adjuvant 030220 oncology & carcinogenesis Surgery Female Neoplasm Recurrence Local business Colorectal Neoplasms Adjuvant |
| Zdroj: | Surgery. 170(4) |
| ISSN: | 1532-7361 |
| Popis: | Background Although liver resection is the only potentially curative treatment for colorectal liver metastases, recurrence is frequent. We previously published the early results of a randomized controlled phase 3 trial showing that adjuvant therapy with uracil-tegafur and leucovorin significantly prolongs recurrence-free survival. This study sought to elucidate the impact of adjuvant chemotherapy on patient survival after an additional follow-up period, building upon the results of our previous study. Methods After resection for colorectal liver metastases, patients were randomly assigned in a 1:1 ratio to receive adjuvant uracil-tegafur and leucovorin or surgery alone. Patients assigned to the uracil-tegafur and leucovorin group received 5 cycles of uracil-tegafur and leucovorin within 8 weeks after surgery. Results Patients were assigned to an adjuvant uracil-tegafur and leucovorin (n = 90) or a surgery alone (n = 90) group; 3 patients were excluded because of protocol violations. After a median follow-up period of 7.36 years (95% confidence interval, 6.93–7.87), 60 (68.2%) patients in the uracil-tegafur and leucovorin group and 61 (68.5%) patients in the surgery alone group developed recurrences. The median recurrence-free survival was 1.45 years (95% confidence interval, 0.96–2.16) in the uracil-tegafur and leucovorin group and 0.70 years (95% confidence interval, 0.44–1.07) in the surgery alone group. The locations and treatments of the first recurrences did not differ between the groups, nor did the overall survival (hazard ratio, 0.86; 95% confidence interval, 0.54–1.38; P = .54). The overall survival was significantly longer in patients who underwent curative repeated resection than in patients who received non-surgical treatment (hazard ratio, 0.25; 95% confidence interval, 0.15–0.40; P Conclusion Adjuvant uracil-tegafur and leucovorin significantly prolonged the recurrence-free survival but not the overall survival. The repeated resection was the most important factor influencing overall survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect